FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
58.988,85 -755,89 (-1,27%)
Avalo Therapeutics, Inc. (AVTX)
Dopo ore:
| Chiusura precedente | 14,98 |
| Aperto | 15,00 |
| Denaro | 15,19 x 100 |
| Lettera | 15,84 x 100 |
| Min-Max giorno | 14,69 - 16,23 |
| Intervallo di 52 settimane | 3,95 - 1.130,40 |
| Volume | |
| Media Volume | 670.388 |
| Capitalizzazione | 16,484M |
| Beta (5 anni mensile) | 1,17 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -114,00 |
| Prossima data utili | 02 mag 2024 - 06 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 35,00 |
GlobeNewswireAvalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation
WAYNE, Pa. and ROCKVILLE, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- In a major achievement, Avalo Therapeutics (Nasdaq: AVTX) proudly announces the payoff of the remainder of its $35 million debt owed to Horizon Technology Finance Corporation (Nasdaq: HRZN). This significant milestone not only signifies the company's steadfast commitment to financial stability but also paves the way for future accelerated growth and progress toward executing its ambitious plans to advance its most promising drug c
- GlobeNewswire
Avalo Enters into Agreement to Divest AVTX-800 Series
WAYNE, Pa. and ROCKVILLE, Md. , Sept. 12, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced it entered into a purchase agreement (the Purchase Agreement) with AUG Therapeutics, LLC (AUG) to sell its rights, title and interest in, assets relating to AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose) (collectively, the 800 Series). AUG will pay an upfront payment of $150,000, as well as, for each compound, make a contingent milestone payment of $15
- GlobeNewswire
Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference
WAYNE, Pa. and ROCKVILLE, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023. The pre-recorded presentation will be made available on Monday, September 11, 2023 at 7:00 AM ET. A webcast of the pre-recorded presentation can be accessed under the “News/Events” page in t
